Companies › Kylonova (Xiamen) Biopharma
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Other; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Kylo-11 Lipoprotein(a) lowering agent | – | Phase 2 | Lipoprotein Disorder | Aug 2028 |
| Kylo-12 | – | Phase 1 | Hypertriglyceridemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06783881 | Kylo-12 | Phase 1 | Hypertriglyceridemia | Metabolic and endocrine | Dec 2025 |
| NCT07327840 | Kylo-11 | Phase 2 | Lipoprotein Disorder | Other | Aug 2028 |
No annotated target.
–
OPKO Health CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Lallemand Health Solutions BrightGene Bio-Medical Technology Sirnaomics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.